<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35527057</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-2518</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>24</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>Vaccine</Title>
          <ISOAbbreviation>Vaccine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.</ArticleTitle>
        <Pagination>
          <StartPage>3305</StartPage>
          <EndPage>3312</EndPage>
          <MedlinePgn>3305-3312</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2022.04.065</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0264-410X(22)00520-5</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Background incidence rates are critical in pharmacovigilance to facilitate identification of vaccine safety signals. We estimated background incidence rates of 11 adverse events of special interest related to COVID-19 vaccines in Ontario, Canada.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a population-based retrospective observational study using linked health administrative databases for hospitalizations and emergency department visits among Ontario residents. We estimated incidence rates of Bell's palsy, idiopathic thrombocytopenia, febrile convulsions, acute disseminated encephalomyelitis, myocarditis, pericarditis, Kawasaki disease, Guillain-Barré syndrome, transverse myelitis, acute myocardial infarction, and anaphylaxis during five pre-pandemic years (2015-2019) and 2020.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The average annual population was 14 million across all age groups with 51% female. The pre-pandemic mean annual rates per 100,000 population during 2015-2019 were 191 for acute myocardial infarction, 43.9 for idiopathic thrombocytopenia, 28.8 for anaphylaxis, 27.8 for Bell's palsy, 25.0 for febrile convulsions, 22.8 for acute disseminated encephalomyelitis, 11.3 for myocarditis/pericarditis, 8.7 for pericarditis, 2.9 for myocarditis, 2.0 for Kawasaki disease, 1.9 for Guillain-Barré syndrome, and 1.7 for transverse myelitis. Females had higher rates of acute disseminated encephalomyelitis, transverse myelitis and anaphylaxis while males had higher rates of myocarditis, pericarditis, and Guillain-Barré syndrome. Bell's palsy, acute disseminated encephalomyelitis, and Guillain-Barré syndrome increased with age. The mean rates of myocarditis and/or pericarditis increased with age up to 79 years; males had higher rates than females: from 12 to 59 years for myocarditis and ≥12 years for pericarditis. Febrile convulsions and Kawasaki disease were predominantly childhood diseases and generally decreased with age.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our estimated background rates will permit estimating numbers of expected events for these conditions and facilitate detection of potential safety signals following COVID-19 vaccination.</AbstractText>
          <CopyrightInformation>Crown Copyright © 2022. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nasreen</LastName>
            <ForeName>Sharifa</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Calzavara</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>ICES, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buchan</LastName>
            <ForeName>Sarah A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada; Public Health Ontario, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thampi</LastName>
            <ForeName>Nisha</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Public Health Ontario, ON, Canada; Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Caitlin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Public Health Ontario, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wilson</LastName>
            <ForeName>Sarah E</ForeName>
            <Initials>SE</Initials>
            <AffiliationInfo>
              <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada; Public Health Ontario, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kwong</LastName>
            <ForeName>Jeffrey C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada; Public Health Ontario, ON, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada. Electronic address: jeff.kwong@utoronto.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Ontario investigators</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Vaccine</MedlineTA>
        <NlmUniqueID>8406899</NlmUniqueID>
        <ISSNLinking>0264-410X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000707" MajorTopicYN="Y">Anaphylaxis</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020330" MajorTopicYN="Y">Bell Palsy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004673" MajorTopicYN="Y">Encephalomyelitis, Acute Disseminated</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009080" MajorTopicYN="Y">Mucocutaneous Lymph Node Syndrome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009188" MajorTopicYN="Y">Myelitis, Transverse</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010493" MajorTopicYN="Y">Pericarditis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016553" MajorTopicYN="Y">Purpura, Thrombocytopenic, Idiopathic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003294" MajorTopicYN="Y">Seizures, Febrile</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Adverse events</Keyword>
        <Keyword MajorTopicYN="N">Background rates</Keyword>
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Incidence rates</Keyword>
        <Keyword MajorTopicYN="N">Vaccine safety</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>22</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35527057</ArticleId>
        <ArticleId IdType="pmc">PMC9042732</ArticleId>
        <ArticleId IdType="doi">10.1016/j.vaccine.2022.04.065</ArticleId>
        <ArticleId IdType="pii">S0264-410X(22)00520-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Health Canada. Drug and vaccine authorizations for COVID-19: List of applications received: Government of Canada; 2021 [Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/applications.html [accessed 23 November 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Health Canada. Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications: Government of Canada; 2021 [Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/list-drugs.html#wb-auto-4 [accessed 23 November 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Health Canada. Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications Ottawa, ON: Government of Canada; 2021 [Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/list-drugs.html [accessed 19 March 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVID-19 viral vector vaccines and rare blood clots – vaccine safety surveillance in action Toronto, ON: Queen’s Printer for Ontario; 2021 [Available from: https://www.publichealthontario.ca/-/media/documents/ncov/vaccines/2021/07/covid-19-viral-vector-vaccines-rare-blood-clots.pdf?sc_lang=en [accessed 6 June 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Medicines and Healthcare products Regulatory Agency (MHRA). Coronavirus vaccine - weekly summary of Yellow Card reporting [Internet]. London (UK): Department of Health and Social Care 2021 [Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting [accessed, 26 October 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Therapeutic Goods Administration (TGA). COVID-19 vaccine weekly safety report [Internet] Canberra: Department of Health, Australian Government; 2021 [Available from: https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-14-10-2021 [accessed, 26 October 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organization (WHO). COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) reviews cases of mild myocarditis reported with COVID-19 mRNA vaccines [Internet] Geneva: WHO; 2021 [Available from: https://www.who.int/news/item/26-05-2021-gacvs-myocarditis-reported-with-covid-19-mrna-vaccines [accessed, 14 June 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Gov.il. Surveillance of myocarditis (inflammation of the heart muscle) cases between December 2020 and May 2021 (including). Press release [Internet] Israel: Ministry of Health; 2021 [Available from: https://www.gov.il/en/departments/news/01062021-03 [accessed, 26 October 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Shimabukuro T. COVID-19 Vaccine Safety Updates. Vaccines and Related Biological Products. Advisory Committee (VRBPAC). [VRBPAC meeting presentation] [Internet] Atlanta: United States Centers for Disease Control and Prevention (CDC), COVID-19 Vaccine Task Force; 2021 [Available from: https://www.fda.gov/media/150054/download [accessed, 20 June 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency (EMA). COVID-19 vaccines: update on ongoing evaluation of myocarditis and pericarditis [Internet] Amsterdam: EMA; 2021 [Available from: https://www.ema.europa.eu/en/news/covid-19-vaccines-update-ongoing-evaluation-myocarditis-pericarditis [accessed, 20 June 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Ontario Agency for Health Protection and Promotion (Public Health Ontario). Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to October 17, 2021 Toronto, ON: Queen’s Printer for Ontario; 2021 [Available from: https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-aefi-report.pdf?sc_lang=en [accessed, 26 October 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Marshall M, Ferguson ID, Lewis P, et al. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. Pediatrics 2021;148(3) doi: 10.1542/peds.2021-052478 [published Online First: 2021/06/06].</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2021-052478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosner C.M., Genovese L., Tehrani B.N., et al.  Myocarditis Temporally Associated With COVID-19 Vaccination. Circulation. 2021;144(6):502–505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8340723</ArticleId>
            <ArticleId IdType="pubmed">34133885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bozkurt B., Kamat I., Hotez P.J. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144(6):471–484. doi: 10.1161/CIRCULATIONAHA.121.056135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.056135</ArticleId>
            <ArticleId IdType="pmc">PMC8340726</ArticleId>
            <ArticleId IdType="pubmed">34281357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buchan SA, Seo CY, Johnson C, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule and interval. medRxiv 2021:2021.12.02.21267156. doi: 10.1101/2021.12.02.21267156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.12.02.21267156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abraham N, Spruin S, Rossi T, et al. Myocarditis and/or Pericarditis Risk After mRNA COVID-19 Vaccination: A Canadian Head to Head Comparison of BNT162b2 and mRNA-1273 Vaccines. JVAC-D-21-03106 2021:Available at SSRN: https://ssrn.com/abstract=3988612.</Citation>
        </Reference>
        <Reference>
          <Citation>Renoud L., Khouri C., Revol B., et al.  Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. JAMA Intern Med. 2021;181(9):1243–1245. doi: 10.1001/jamainternmed.2021.2219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamainternmed.2021.2219</ArticleId>
            <ArticleId IdType="pmc">PMC8080152</ArticleId>
            <ArticleId IdType="pubmed">33904857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barré Syndrome (GBS) following adenovirus vector COVID-19 vaccines 2021 [Available from: https://www.who.int/news/item/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs [accessed 10 August, 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency (EMA). COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB Public Statement 2021 [Available from: https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-july-2021_en.pdf [accessed 10 August, 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Advisory Committee on Immunization Practices (ACIP). Guillain-Barré Syndrome (GBS) after Janssen COVID-19 Vaccine: Vaccine Adverse Event Reporting System (VAERS). Meeting of the Advisory Committee on Immunization Practices (ACIP), July 22, 2021; 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Shimabukuro T.T., Cole M., Su J.R. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101–1102. doi: 10.1001/jama.2021.1967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.1967</ArticleId>
            <ArticleId IdType="pmc">PMC8890485</ArticleId>
            <ArticleId IdType="pubmed">33576785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sobczak M., Pawliczak R. The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis. Clin Mol Allergy. 2022;20(1):1. doi: 10.1186/s12948-022-00167-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12948-022-00167-y</ArticleId>
            <ArticleId IdType="pmc">PMC8762434</ArticleId>
            <ArticleId IdType="pubmed">35039051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barda N., Dagan N., Ben-Shlomo Y., et al.  Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2021;385(12):1078–1090. doi: 10.1056/NEJMoa2110475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2110475</ArticleId>
            <ArticleId IdType="pmc">PMC8427535</ArticleId>
            <ArticleId IdType="pubmed">34432976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein N.P., Lewis N., Goddard K., et al.  Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021;326(14):1390–1399. doi: 10.1001/jama.2021.15072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.15072</ArticleId>
            <ArticleId IdType="pmc">PMC8511971</ArticleId>
            <ArticleId IdType="pubmed">34477808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jabagi M.J., Botton J., Bertrand M., et al.  Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older. JAMA. 2022;327(1):80–82. doi: 10.1001/jama.2021.21699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.21699</ArticleId>
            <ArticleId IdType="pmc">PMC8609457</ArticleId>
            <ArticleId IdType="pubmed">34807248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee October 26, 2021 Meeting Document. BNT162B2 [COMIRNATY (COVID-19 VACCINE, MRNA)]: Food and Drug Administration (FDA); 2021 [Available from: https://www.fda.gov/media/153409/download [accessed, 26 October 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention (CDC). CDC Recommends Pediatric COVID-19 Vaccine for Children 5 to 11 Years 2021 [Available from: https://www.cdc.gov/media/releases/2021/s1102-PediatricCOVID-19Vaccine.html [accessed 3 November 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Health Canada. Health Canada authorizes use of Comirnaty (the Pfizer-BioNTech COVID-19 vaccine) in children 5 to 11 years of age: Government of Canada; 2021 [Available from: https://www.canada.ca/en/health-canada/news/2021/11/health-canada-authorizes-use-of-comirnaty-the-pfizer-biontech-covid-19-vaccine-in-children-5-to-11-years-of-age.html [accessed 19 November 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>National Advisory Committee on Immunization (NACI). An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5-11 years of age. Ottawa, ON: Government of Canada; 2021 [Available from: https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/pfizer-biontech-10-mcg-children-5-11-years-age/pfizer-biontech-10-mcg-children-5-11-years-age.pdf [accessed 19 November 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Lopalco P.L., DeStefano F. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines. Vaccine. 2015;33(13):1541–1548. doi: 10.1016/j.vaccine.2014.10.047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2014.10.047</ArticleId>
            <ArticleId IdType="pmc">PMC4596394</ArticleId>
            <ArticleId IdType="pubmed">25444788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Black S.B., Law B., Chen R.T., et al.  The Critical Role Background Rates of Possible Adverse Events in the Assessment of COVID-19 Vaccine Safety. Vaccine. 2021 doi: 10.1016/j.vaccine.2021.03.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2021.03.016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Black S., Eskola J., Siegrist C.-A., et al.  Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet. 2009;374(9707):2115–2122. doi: 10.1016/S0140-6736(09)61877-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(09)61877-8</ArticleId>
            <ArticleId IdType="pmc">PMC2861912</ArticleId>
            <ArticleId IdType="pubmed">19880172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deeks S.L., Lim G.H., Simpson M.A., et al.  Estimating background rates of Guillain-Barre Syndrome in Ontario in order to respond to safety concerns during pandemic H1N1/09 immunization campaign. BMC Public Health. 2011;11:329. doi: 10.1186/1471-2458-11-329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2458-11-329</ArticleId>
            <ArticleId IdType="pmc">PMC3112136</ArticleId>
            <ArticleId IdType="pubmed">21586163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Wu L., Yu X., et al.  The Expected Number of Background Disease Events during Mass Immunization in China. PLoS One. 2013;8(8) doi: 10.1371/journal.pone.0071818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0071818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasreen S., Calzavara A.J., Sundaram M.E., et al.  Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study. BMJ Open. 2021;11(12)</Citation>
        </Reference>
        <Reference>
          <Citation>Gubernot D, Jazwa A, Niu M, et al. U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines. Vaccine 2021;39(28):3666–77. doi: 10.1016/j.vaccine.2021.05.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2021.05.016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X., Ostropolets A., Makadia R., et al.  Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021;373 doi: 10.1136/bmj.n1435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n1435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>International statistical classification of diseases and related health problems, tenth revision, Canada (ICD-10-CA). Ottawa, Ontario, Canada: Canadian Institute for Health Information; 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Wormsbecker A.E., Johnson C., Bourns L., et al.  Demonstration of background rates of three conditions of interest for vaccine safety surveillance. PLoS One. 2019;14(1) doi: 10.1371/journal.pone.0210833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0210833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willame C., Dodd C., Gini R., et al.  Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines (2.0) Zenodo. 2021 doi: 10.5281/zenodo.5255870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5281/zenodo.5255870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fay M.P., Feuer E.J. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med. 1997;16(7):791–801. doi: 10.1002/(sici)1097-0258(19970415)16:7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(sici)1097-0258(19970415)16:7</ArticleId>
            <ArticleId IdType="pubmed">9131766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kytö V., Sipilä J., Rautava P. The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood. Heart. 2013;99(22):1681–1684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24064227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vasudeva R., Bhatt P., Lilje C., et al.  Trends in Acute Myocarditis Related Pediatric Hospitalizations in the United States, 2007–2016. Am J Cardiol. 2021;149:95–102. doi: 10.1016/j.amjcard.2021.03.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjcard.2021.03.019</ArticleId>
            <ArticleId IdType="pubmed">33757784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ontario Agency for Health Protection and Promotion (Public Health Ontario). Ontario respiratory pathogen bulletin [Internet]. Toronto, ON: Queen’s Printer for Ontario; 2021 [Available from: https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/respiratory-pathogens-weekly/respiratory-pathogens-historical [accessed November 25 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Government of Ontario. Guide to reopening Ontario’s schools: Queen's Printer for Ontario; 2020 [Available from: https://www.ontario.ca/page/guide-reopening-ontarios-schools [accessed November 25 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Bhatia R.S., Chu C., Pang A., et al.  Virtual care use before and during the COVID-19 pandemic: a repeated cross-sectional study. CMAJ Open. 2021;9(1):E107. doi: 10.9778/cmajo.20200311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.9778/cmajo.20200311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rasmussen T.A., Jørgensen M.R.S., Bjerrum S., et al.  Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. BMJ. 2012;345 doi: 10.1136/bmj.e5823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.e5823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burns J.C., Herzog L., Fabri O., et al.  Seasonality of Kawasaki disease: a global perspective. PLoS One. 2013;8(9):e74529–e74629. doi: 10.1371/journal.pone.0074529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0074529</ArticleId>
            <ArticleId IdType="pmc">PMC3776809</ArticleId>
            <ArticleId IdType="pubmed">24058585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mikkonen K., Uhari M., Pokka T., et al.  Diurnal and seasonal occurrence of febrile seizures. Pediatr Neurol. 2015;52(4):424–427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25682483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juurlink D, Preyra C, Croxford R, et al. Canadian Institute for Health Information Discharge Abstract Database: A Validation Study Toronto: Institute for Clinical Evaluative Sciences; 2006 [Available from: https://www.ices.on.ca/flip-publication/canadian-istitute-for-health-information-discharge/files/assets/basic-html/index.html#9.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35527057</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-2518</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>24</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>Vaccine</Title>
          <ISOAbbreviation>Vaccine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.</ArticleTitle>
        <Pagination>
          <StartPage>3305</StartPage>
          <EndPage>3312</EndPage>
          <MedlinePgn>3305-3312</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2022.04.065</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0264-410X(22)00520-5</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Background incidence rates are critical in pharmacovigilance to facilitate identification of vaccine safety signals. We estimated background incidence rates of 11 adverse events of special interest related to COVID-19 vaccines in Ontario, Canada.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a population-based retrospective observational study using linked health administrative databases for hospitalizations and emergency department visits among Ontario residents. We estimated incidence rates of Bell's palsy, idiopathic thrombocytopenia, febrile convulsions, acute disseminated encephalomyelitis, myocarditis, pericarditis, Kawasaki disease, Guillain-Barré syndrome, transverse myelitis, acute myocardial infarction, and anaphylaxis during five pre-pandemic years (2015-2019) and 2020.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The average annual population was 14 million across all age groups with 51% female. The pre-pandemic mean annual rates per 100,000 population during 2015-2019 were 191 for acute myocardial infarction, 43.9 for idiopathic thrombocytopenia, 28.8 for anaphylaxis, 27.8 for Bell's palsy, 25.0 for febrile convulsions, 22.8 for acute disseminated encephalomyelitis, 11.3 for myocarditis/pericarditis, 8.7 for pericarditis, 2.9 for myocarditis, 2.0 for Kawasaki disease, 1.9 for Guillain-Barré syndrome, and 1.7 for transverse myelitis. Females had higher rates of acute disseminated encephalomyelitis, transverse myelitis and anaphylaxis while males had higher rates of myocarditis, pericarditis, and Guillain-Barré syndrome. Bell's palsy, acute disseminated encephalomyelitis, and Guillain-Barré syndrome increased with age. The mean rates of myocarditis and/or pericarditis increased with age up to 79 years; males had higher rates than females: from 12 to 59 years for myocarditis and ≥12 years for pericarditis. Febrile convulsions and Kawasaki disease were predominantly childhood diseases and generally decreased with age.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our estimated background rates will permit estimating numbers of expected events for these conditions and facilitate detection of potential safety signals following COVID-19 vaccination.</AbstractText>
          <CopyrightInformation>Crown Copyright © 2022. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nasreen</LastName>
            <ForeName>Sharifa</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Calzavara</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>ICES, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buchan</LastName>
            <ForeName>Sarah A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada; Public Health Ontario, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thampi</LastName>
            <ForeName>Nisha</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Public Health Ontario, ON, Canada; Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Caitlin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Public Health Ontario, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wilson</LastName>
            <ForeName>Sarah E</ForeName>
            <Initials>SE</Initials>
            <AffiliationInfo>
              <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada; Public Health Ontario, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kwong</LastName>
            <ForeName>Jeffrey C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada; Public Health Ontario, ON, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada. Electronic address: jeff.kwong@utoronto.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Ontario investigators</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Vaccine</MedlineTA>
        <NlmUniqueID>8406899</NlmUniqueID>
        <ISSNLinking>0264-410X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000707" MajorTopicYN="Y">Anaphylaxis</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020330" MajorTopicYN="Y">Bell Palsy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004673" MajorTopicYN="Y">Encephalomyelitis, Acute Disseminated</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009080" MajorTopicYN="Y">Mucocutaneous Lymph Node Syndrome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009188" MajorTopicYN="Y">Myelitis, Transverse</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010493" MajorTopicYN="Y">Pericarditis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016553" MajorTopicYN="Y">Purpura, Thrombocytopenic, Idiopathic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003294" MajorTopicYN="Y">Seizures, Febrile</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Adverse events</Keyword>
        <Keyword MajorTopicYN="N">Background rates</Keyword>
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Incidence rates</Keyword>
        <Keyword MajorTopicYN="N">Vaccine safety</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>22</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35527057</ArticleId>
        <ArticleId IdType="pmc">PMC9042732</ArticleId>
        <ArticleId IdType="doi">10.1016/j.vaccine.2022.04.065</ArticleId>
        <ArticleId IdType="pii">S0264-410X(22)00520-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Health Canada. Drug and vaccine authorizations for COVID-19: List of applications received: Government of Canada; 2021 [Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/applications.html [accessed 23 November 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Health Canada. Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications: Government of Canada; 2021 [Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/list-drugs.html#wb-auto-4 [accessed 23 November 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Health Canada. Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications Ottawa, ON: Government of Canada; 2021 [Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/list-drugs.html [accessed 19 March 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVID-19 viral vector vaccines and rare blood clots – vaccine safety surveillance in action Toronto, ON: Queen’s Printer for Ontario; 2021 [Available from: https://www.publichealthontario.ca/-/media/documents/ncov/vaccines/2021/07/covid-19-viral-vector-vaccines-rare-blood-clots.pdf?sc_lang=en [accessed 6 June 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Medicines and Healthcare products Regulatory Agency (MHRA). Coronavirus vaccine - weekly summary of Yellow Card reporting [Internet]. London (UK): Department of Health and Social Care 2021 [Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting [accessed, 26 October 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Therapeutic Goods Administration (TGA). COVID-19 vaccine weekly safety report [Internet] Canberra: Department of Health, Australian Government; 2021 [Available from: https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-14-10-2021 [accessed, 26 October 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organization (WHO). COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) reviews cases of mild myocarditis reported with COVID-19 mRNA vaccines [Internet] Geneva: WHO; 2021 [Available from: https://www.who.int/news/item/26-05-2021-gacvs-myocarditis-reported-with-covid-19-mrna-vaccines [accessed, 14 June 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Gov.il. Surveillance of myocarditis (inflammation of the heart muscle) cases between December 2020 and May 2021 (including). Press release [Internet] Israel: Ministry of Health; 2021 [Available from: https://www.gov.il/en/departments/news/01062021-03 [accessed, 26 October 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Shimabukuro T. COVID-19 Vaccine Safety Updates. Vaccines and Related Biological Products. Advisory Committee (VRBPAC). [VRBPAC meeting presentation] [Internet] Atlanta: United States Centers for Disease Control and Prevention (CDC), COVID-19 Vaccine Task Force; 2021 [Available from: https://www.fda.gov/media/150054/download [accessed, 20 June 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency (EMA). COVID-19 vaccines: update on ongoing evaluation of myocarditis and pericarditis [Internet] Amsterdam: EMA; 2021 [Available from: https://www.ema.europa.eu/en/news/covid-19-vaccines-update-ongoing-evaluation-myocarditis-pericarditis [accessed, 20 June 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Ontario Agency for Health Protection and Promotion (Public Health Ontario). Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to October 17, 2021 Toronto, ON: Queen’s Printer for Ontario; 2021 [Available from: https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-aefi-report.pdf?sc_lang=en [accessed, 26 October 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Marshall M, Ferguson ID, Lewis P, et al. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. Pediatrics 2021;148(3) doi: 10.1542/peds.2021-052478 [published Online First: 2021/06/06].</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2021-052478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosner C.M., Genovese L., Tehrani B.N., et al.  Myocarditis Temporally Associated With COVID-19 Vaccination. Circulation. 2021;144(6):502–505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8340723</ArticleId>
            <ArticleId IdType="pubmed">34133885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bozkurt B., Kamat I., Hotez P.J. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144(6):471–484. doi: 10.1161/CIRCULATIONAHA.121.056135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.056135</ArticleId>
            <ArticleId IdType="pmc">PMC8340726</ArticleId>
            <ArticleId IdType="pubmed">34281357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buchan SA, Seo CY, Johnson C, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule and interval. medRxiv 2021:2021.12.02.21267156. doi: 10.1101/2021.12.02.21267156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.12.02.21267156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abraham N, Spruin S, Rossi T, et al. Myocarditis and/or Pericarditis Risk After mRNA COVID-19 Vaccination: A Canadian Head to Head Comparison of BNT162b2 and mRNA-1273 Vaccines. JVAC-D-21-03106 2021:Available at SSRN: https://ssrn.com/abstract=3988612.</Citation>
        </Reference>
        <Reference>
          <Citation>Renoud L., Khouri C., Revol B., et al.  Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. JAMA Intern Med. 2021;181(9):1243–1245. doi: 10.1001/jamainternmed.2021.2219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamainternmed.2021.2219</ArticleId>
            <ArticleId IdType="pmc">PMC8080152</ArticleId>
            <ArticleId IdType="pubmed">33904857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barré Syndrome (GBS) following adenovirus vector COVID-19 vaccines 2021 [Available from: https://www.who.int/news/item/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs [accessed 10 August, 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency (EMA). COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB Public Statement 2021 [Available from: https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-july-2021_en.pdf [accessed 10 August, 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Advisory Committee on Immunization Practices (ACIP). Guillain-Barré Syndrome (GBS) after Janssen COVID-19 Vaccine: Vaccine Adverse Event Reporting System (VAERS). Meeting of the Advisory Committee on Immunization Practices (ACIP), July 22, 2021; 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Shimabukuro T.T., Cole M., Su J.R. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101–1102. doi: 10.1001/jama.2021.1967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.1967</ArticleId>
            <ArticleId IdType="pmc">PMC8890485</ArticleId>
            <ArticleId IdType="pubmed">33576785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sobczak M., Pawliczak R. The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis. Clin Mol Allergy. 2022;20(1):1. doi: 10.1186/s12948-022-00167-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12948-022-00167-y</ArticleId>
            <ArticleId IdType="pmc">PMC8762434</ArticleId>
            <ArticleId IdType="pubmed">35039051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barda N., Dagan N., Ben-Shlomo Y., et al.  Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2021;385(12):1078–1090. doi: 10.1056/NEJMoa2110475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2110475</ArticleId>
            <ArticleId IdType="pmc">PMC8427535</ArticleId>
            <ArticleId IdType="pubmed">34432976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein N.P., Lewis N., Goddard K., et al.  Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021;326(14):1390–1399. doi: 10.1001/jama.2021.15072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.15072</ArticleId>
            <ArticleId IdType="pmc">PMC8511971</ArticleId>
            <ArticleId IdType="pubmed">34477808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jabagi M.J., Botton J., Bertrand M., et al.  Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older. JAMA. 2022;327(1):80–82. doi: 10.1001/jama.2021.21699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.21699</ArticleId>
            <ArticleId IdType="pmc">PMC8609457</ArticleId>
            <ArticleId IdType="pubmed">34807248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee October 26, 2021 Meeting Document. BNT162B2 [COMIRNATY (COVID-19 VACCINE, MRNA)]: Food and Drug Administration (FDA); 2021 [Available from: https://www.fda.gov/media/153409/download [accessed, 26 October 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention (CDC). CDC Recommends Pediatric COVID-19 Vaccine for Children 5 to 11 Years 2021 [Available from: https://www.cdc.gov/media/releases/2021/s1102-PediatricCOVID-19Vaccine.html [accessed 3 November 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Health Canada. Health Canada authorizes use of Comirnaty (the Pfizer-BioNTech COVID-19 vaccine) in children 5 to 11 years of age: Government of Canada; 2021 [Available from: https://www.canada.ca/en/health-canada/news/2021/11/health-canada-authorizes-use-of-comirnaty-the-pfizer-biontech-covid-19-vaccine-in-children-5-to-11-years-of-age.html [accessed 19 November 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>National Advisory Committee on Immunization (NACI). An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5-11 years of age. Ottawa, ON: Government of Canada; 2021 [Available from: https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/pfizer-biontech-10-mcg-children-5-11-years-age/pfizer-biontech-10-mcg-children-5-11-years-age.pdf [accessed 19 November 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Lopalco P.L., DeStefano F. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines. Vaccine. 2015;33(13):1541–1548. doi: 10.1016/j.vaccine.2014.10.047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2014.10.047</ArticleId>
            <ArticleId IdType="pmc">PMC4596394</ArticleId>
            <ArticleId IdType="pubmed">25444788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Black S.B., Law B., Chen R.T., et al.  The Critical Role Background Rates of Possible Adverse Events in the Assessment of COVID-19 Vaccine Safety. Vaccine. 2021 doi: 10.1016/j.vaccine.2021.03.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2021.03.016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Black S., Eskola J., Siegrist C.-A., et al.  Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet. 2009;374(9707):2115–2122. doi: 10.1016/S0140-6736(09)61877-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(09)61877-8</ArticleId>
            <ArticleId IdType="pmc">PMC2861912</ArticleId>
            <ArticleId IdType="pubmed">19880172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deeks S.L., Lim G.H., Simpson M.A., et al.  Estimating background rates of Guillain-Barre Syndrome in Ontario in order to respond to safety concerns during pandemic H1N1/09 immunization campaign. BMC Public Health. 2011;11:329. doi: 10.1186/1471-2458-11-329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2458-11-329</ArticleId>
            <ArticleId IdType="pmc">PMC3112136</ArticleId>
            <ArticleId IdType="pubmed">21586163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Wu L., Yu X., et al.  The Expected Number of Background Disease Events during Mass Immunization in China. PLoS One. 2013;8(8) doi: 10.1371/journal.pone.0071818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0071818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasreen S., Calzavara A.J., Sundaram M.E., et al.  Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study. BMJ Open. 2021;11(12)</Citation>
        </Reference>
        <Reference>
          <Citation>Gubernot D, Jazwa A, Niu M, et al. U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines. Vaccine 2021;39(28):3666–77. doi: 10.1016/j.vaccine.2021.05.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2021.05.016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X., Ostropolets A., Makadia R., et al.  Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021;373 doi: 10.1136/bmj.n1435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n1435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>International statistical classification of diseases and related health problems, tenth revision, Canada (ICD-10-CA). Ottawa, Ontario, Canada: Canadian Institute for Health Information; 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Wormsbecker A.E., Johnson C., Bourns L., et al.  Demonstration of background rates of three conditions of interest for vaccine safety surveillance. PLoS One. 2019;14(1) doi: 10.1371/journal.pone.0210833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0210833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willame C., Dodd C., Gini R., et al.  Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines (2.0) Zenodo. 2021 doi: 10.5281/zenodo.5255870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5281/zenodo.5255870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fay M.P., Feuer E.J. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med. 1997;16(7):791–801. doi: 10.1002/(sici)1097-0258(19970415)16:7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(sici)1097-0258(19970415)16:7</ArticleId>
            <ArticleId IdType="pubmed">9131766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kytö V., Sipilä J., Rautava P. The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood. Heart. 2013;99(22):1681–1684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24064227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vasudeva R., Bhatt P., Lilje C., et al.  Trends in Acute Myocarditis Related Pediatric Hospitalizations in the United States, 2007–2016. Am J Cardiol. 2021;149:95–102. doi: 10.1016/j.amjcard.2021.03.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjcard.2021.03.019</ArticleId>
            <ArticleId IdType="pubmed">33757784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ontario Agency for Health Protection and Promotion (Public Health Ontario). Ontario respiratory pathogen bulletin [Internet]. Toronto, ON: Queen’s Printer for Ontario; 2021 [Available from: https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/respiratory-pathogens-weekly/respiratory-pathogens-historical [accessed November 25 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Government of Ontario. Guide to reopening Ontario’s schools: Queen's Printer for Ontario; 2020 [Available from: https://www.ontario.ca/page/guide-reopening-ontarios-schools [accessed November 25 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Bhatia R.S., Chu C., Pang A., et al.  Virtual care use before and during the COVID-19 pandemic: a repeated cross-sectional study. CMAJ Open. 2021;9(1):E107. doi: 10.9778/cmajo.20200311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.9778/cmajo.20200311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rasmussen T.A., Jørgensen M.R.S., Bjerrum S., et al.  Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. BMJ. 2012;345 doi: 10.1136/bmj.e5823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.e5823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burns J.C., Herzog L., Fabri O., et al.  Seasonality of Kawasaki disease: a global perspective. PLoS One. 2013;8(9):e74529–e74629. doi: 10.1371/journal.pone.0074529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0074529</ArticleId>
            <ArticleId IdType="pmc">PMC3776809</ArticleId>
            <ArticleId IdType="pubmed">24058585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mikkonen K., Uhari M., Pokka T., et al.  Diurnal and seasonal occurrence of febrile seizures. Pediatr Neurol. 2015;52(4):424–427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25682483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juurlink D, Preyra C, Croxford R, et al. Canadian Institute for Health Information Discharge Abstract Database: A Validation Study Toronto: Institute for Clinical Evaluative Sciences; 2006 [Available from: https://www.ices.on.ca/flip-publication/canadian-istitute-for-health-information-discharge/files/assets/basic-html/index.html#9.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35527057</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-2518</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>24</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>Vaccine</Title>
          <ISOAbbreviation>Vaccine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.</ArticleTitle>
        <Pagination>
          <StartPage>3305</StartPage>
          <EndPage>3312</EndPage>
          <MedlinePgn>3305-3312</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2022.04.065</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0264-410X(22)00520-5</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Background incidence rates are critical in pharmacovigilance to facilitate identification of vaccine safety signals. We estimated background incidence rates of 11 adverse events of special interest related to COVID-19 vaccines in Ontario, Canada.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a population-based retrospective observational study using linked health administrative databases for hospitalizations and emergency department visits among Ontario residents. We estimated incidence rates of Bell's palsy, idiopathic thrombocytopenia, febrile convulsions, acute disseminated encephalomyelitis, myocarditis, pericarditis, Kawasaki disease, Guillain-Barré syndrome, transverse myelitis, acute myocardial infarction, and anaphylaxis during five pre-pandemic years (2015-2019) and 2020.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The average annual population was 14 million across all age groups with 51% female. The pre-pandemic mean annual rates per 100,000 population during 2015-2019 were 191 for acute myocardial infarction, 43.9 for idiopathic thrombocytopenia, 28.8 for anaphylaxis, 27.8 for Bell's palsy, 25.0 for febrile convulsions, 22.8 for acute disseminated encephalomyelitis, 11.3 for myocarditis/pericarditis, 8.7 for pericarditis, 2.9 for myocarditis, 2.0 for Kawasaki disease, 1.9 for Guillain-Barré syndrome, and 1.7 for transverse myelitis. Females had higher rates of acute disseminated encephalomyelitis, transverse myelitis and anaphylaxis while males had higher rates of myocarditis, pericarditis, and Guillain-Barré syndrome. Bell's palsy, acute disseminated encephalomyelitis, and Guillain-Barré syndrome increased with age. The mean rates of myocarditis and/or pericarditis increased with age up to 79 years; males had higher rates than females: from 12 to 59 years for myocarditis and ≥12 years for pericarditis. Febrile convulsions and Kawasaki disease were predominantly childhood diseases and generally decreased with age.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our estimated background rates will permit estimating numbers of expected events for these conditions and facilitate detection of potential safety signals following COVID-19 vaccination.</AbstractText>
          <CopyrightInformation>Crown Copyright © 2022. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nasreen</LastName>
            <ForeName>Sharifa</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Calzavara</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>ICES, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buchan</LastName>
            <ForeName>Sarah A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada; Public Health Ontario, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thampi</LastName>
            <ForeName>Nisha</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Public Health Ontario, ON, Canada; Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Caitlin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Public Health Ontario, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wilson</LastName>
            <ForeName>Sarah E</ForeName>
            <Initials>SE</Initials>
            <AffiliationInfo>
              <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada; Public Health Ontario, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kwong</LastName>
            <ForeName>Jeffrey C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada; Public Health Ontario, ON, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada. Electronic address: jeff.kwong@utoronto.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Ontario investigators</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Vaccine</MedlineTA>
        <NlmUniqueID>8406899</NlmUniqueID>
        <ISSNLinking>0264-410X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000707" MajorTopicYN="Y">Anaphylaxis</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020330" MajorTopicYN="Y">Bell Palsy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004673" MajorTopicYN="Y">Encephalomyelitis, Acute Disseminated</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009080" MajorTopicYN="Y">Mucocutaneous Lymph Node Syndrome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009188" MajorTopicYN="Y">Myelitis, Transverse</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010493" MajorTopicYN="Y">Pericarditis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016553" MajorTopicYN="Y">Purpura, Thrombocytopenic, Idiopathic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003294" MajorTopicYN="Y">Seizures, Febrile</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Adverse events</Keyword>
        <Keyword MajorTopicYN="N">Background rates</Keyword>
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">Incidence rates</Keyword>
        <Keyword MajorTopicYN="N">Vaccine safety</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>22</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35527057</ArticleId>
        <ArticleId IdType="pmc">PMC9042732</ArticleId>
        <ArticleId IdType="doi">10.1016/j.vaccine.2022.04.065</ArticleId>
        <ArticleId IdType="pii">S0264-410X(22)00520-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Health Canada. Drug and vaccine authorizations for COVID-19: List of applications received: Government of Canada; 2021 [Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/applications.html [accessed 23 November 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Health Canada. Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications: Government of Canada; 2021 [Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/list-drugs.html#wb-auto-4 [accessed 23 November 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Health Canada. Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications Ottawa, ON: Government of Canada; 2021 [Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/list-drugs.html [accessed 19 March 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVID-19 viral vector vaccines and rare blood clots – vaccine safety surveillance in action Toronto, ON: Queen’s Printer for Ontario; 2021 [Available from: https://www.publichealthontario.ca/-/media/documents/ncov/vaccines/2021/07/covid-19-viral-vector-vaccines-rare-blood-clots.pdf?sc_lang=en [accessed 6 June 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Medicines and Healthcare products Regulatory Agency (MHRA). Coronavirus vaccine - weekly summary of Yellow Card reporting [Internet]. London (UK): Department of Health and Social Care 2021 [Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting [accessed, 26 October 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Therapeutic Goods Administration (TGA). COVID-19 vaccine weekly safety report [Internet] Canberra: Department of Health, Australian Government; 2021 [Available from: https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-14-10-2021 [accessed, 26 October 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organization (WHO). COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) reviews cases of mild myocarditis reported with COVID-19 mRNA vaccines [Internet] Geneva: WHO; 2021 [Available from: https://www.who.int/news/item/26-05-2021-gacvs-myocarditis-reported-with-covid-19-mrna-vaccines [accessed, 14 June 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Gov.il. Surveillance of myocarditis (inflammation of the heart muscle) cases between December 2020 and May 2021 (including). Press release [Internet] Israel: Ministry of Health; 2021 [Available from: https://www.gov.il/en/departments/news/01062021-03 [accessed, 26 October 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Shimabukuro T. COVID-19 Vaccine Safety Updates. Vaccines and Related Biological Products. Advisory Committee (VRBPAC). [VRBPAC meeting presentation] [Internet] Atlanta: United States Centers for Disease Control and Prevention (CDC), COVID-19 Vaccine Task Force; 2021 [Available from: https://www.fda.gov/media/150054/download [accessed, 20 June 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency (EMA). COVID-19 vaccines: update on ongoing evaluation of myocarditis and pericarditis [Internet] Amsterdam: EMA; 2021 [Available from: https://www.ema.europa.eu/en/news/covid-19-vaccines-update-ongoing-evaluation-myocarditis-pericarditis [accessed, 20 June 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Ontario Agency for Health Protection and Promotion (Public Health Ontario). Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to October 17, 2021 Toronto, ON: Queen’s Printer for Ontario; 2021 [Available from: https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-aefi-report.pdf?sc_lang=en [accessed, 26 October 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Marshall M, Ferguson ID, Lewis P, et al. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. Pediatrics 2021;148(3) doi: 10.1542/peds.2021-052478 [published Online First: 2021/06/06].</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2021-052478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosner C.M., Genovese L., Tehrani B.N., et al.  Myocarditis Temporally Associated With COVID-19 Vaccination. Circulation. 2021;144(6):502–505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8340723</ArticleId>
            <ArticleId IdType="pubmed">34133885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bozkurt B., Kamat I., Hotez P.J. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144(6):471–484. doi: 10.1161/CIRCULATIONAHA.121.056135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.056135</ArticleId>
            <ArticleId IdType="pmc">PMC8340726</ArticleId>
            <ArticleId IdType="pubmed">34281357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buchan SA, Seo CY, Johnson C, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule and interval. medRxiv 2021:2021.12.02.21267156. doi: 10.1101/2021.12.02.21267156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.12.02.21267156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abraham N, Spruin S, Rossi T, et al. Myocarditis and/or Pericarditis Risk After mRNA COVID-19 Vaccination: A Canadian Head to Head Comparison of BNT162b2 and mRNA-1273 Vaccines. JVAC-D-21-03106 2021:Available at SSRN: https://ssrn.com/abstract=3988612.</Citation>
        </Reference>
        <Reference>
          <Citation>Renoud L., Khouri C., Revol B., et al.  Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. JAMA Intern Med. 2021;181(9):1243–1245. doi: 10.1001/jamainternmed.2021.2219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamainternmed.2021.2219</ArticleId>
            <ArticleId IdType="pmc">PMC8080152</ArticleId>
            <ArticleId IdType="pubmed">33904857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barré Syndrome (GBS) following adenovirus vector COVID-19 vaccines 2021 [Available from: https://www.who.int/news/item/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs [accessed 10 August, 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency (EMA). COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB Public Statement 2021 [Available from: https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-july-2021_en.pdf [accessed 10 August, 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Advisory Committee on Immunization Practices (ACIP). Guillain-Barré Syndrome (GBS) after Janssen COVID-19 Vaccine: Vaccine Adverse Event Reporting System (VAERS). Meeting of the Advisory Committee on Immunization Practices (ACIP), July 22, 2021; 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Shimabukuro T.T., Cole M., Su J.R. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101–1102. doi: 10.1001/jama.2021.1967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.1967</ArticleId>
            <ArticleId IdType="pmc">PMC8890485</ArticleId>
            <ArticleId IdType="pubmed">33576785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sobczak M., Pawliczak R. The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis. Clin Mol Allergy. 2022;20(1):1. doi: 10.1186/s12948-022-00167-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12948-022-00167-y</ArticleId>
            <ArticleId IdType="pmc">PMC8762434</ArticleId>
            <ArticleId IdType="pubmed">35039051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barda N., Dagan N., Ben-Shlomo Y., et al.  Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2021;385(12):1078–1090. doi: 10.1056/NEJMoa2110475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2110475</ArticleId>
            <ArticleId IdType="pmc">PMC8427535</ArticleId>
            <ArticleId IdType="pubmed">34432976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein N.P., Lewis N., Goddard K., et al.  Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021;326(14):1390–1399. doi: 10.1001/jama.2021.15072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.15072</ArticleId>
            <ArticleId IdType="pmc">PMC8511971</ArticleId>
            <ArticleId IdType="pubmed">34477808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jabagi M.J., Botton J., Bertrand M., et al.  Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older. JAMA. 2022;327(1):80–82. doi: 10.1001/jama.2021.21699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.21699</ArticleId>
            <ArticleId IdType="pmc">PMC8609457</ArticleId>
            <ArticleId IdType="pubmed">34807248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee October 26, 2021 Meeting Document. BNT162B2 [COMIRNATY (COVID-19 VACCINE, MRNA)]: Food and Drug Administration (FDA); 2021 [Available from: https://www.fda.gov/media/153409/download [accessed, 26 October 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention (CDC). CDC Recommends Pediatric COVID-19 Vaccine for Children 5 to 11 Years 2021 [Available from: https://www.cdc.gov/media/releases/2021/s1102-PediatricCOVID-19Vaccine.html [accessed 3 November 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Health Canada. Health Canada authorizes use of Comirnaty (the Pfizer-BioNTech COVID-19 vaccine) in children 5 to 11 years of age: Government of Canada; 2021 [Available from: https://www.canada.ca/en/health-canada/news/2021/11/health-canada-authorizes-use-of-comirnaty-the-pfizer-biontech-covid-19-vaccine-in-children-5-to-11-years-of-age.html [accessed 19 November 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>National Advisory Committee on Immunization (NACI). An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5-11 years of age. Ottawa, ON: Government of Canada; 2021 [Available from: https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/pfizer-biontech-10-mcg-children-5-11-years-age/pfizer-biontech-10-mcg-children-5-11-years-age.pdf [accessed 19 November 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Lopalco P.L., DeStefano F. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines. Vaccine. 2015;33(13):1541–1548. doi: 10.1016/j.vaccine.2014.10.047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2014.10.047</ArticleId>
            <ArticleId IdType="pmc">PMC4596394</ArticleId>
            <ArticleId IdType="pubmed">25444788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Black S.B., Law B., Chen R.T., et al.  The Critical Role Background Rates of Possible Adverse Events in the Assessment of COVID-19 Vaccine Safety. Vaccine. 2021 doi: 10.1016/j.vaccine.2021.03.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2021.03.016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Black S., Eskola J., Siegrist C.-A., et al.  Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet. 2009;374(9707):2115–2122. doi: 10.1016/S0140-6736(09)61877-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(09)61877-8</ArticleId>
            <ArticleId IdType="pmc">PMC2861912</ArticleId>
            <ArticleId IdType="pubmed">19880172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deeks S.L., Lim G.H., Simpson M.A., et al.  Estimating background rates of Guillain-Barre Syndrome in Ontario in order to respond to safety concerns during pandemic H1N1/09 immunization campaign. BMC Public Health. 2011;11:329. doi: 10.1186/1471-2458-11-329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2458-11-329</ArticleId>
            <ArticleId IdType="pmc">PMC3112136</ArticleId>
            <ArticleId IdType="pubmed">21586163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Wu L., Yu X., et al.  The Expected Number of Background Disease Events during Mass Immunization in China. PLoS One. 2013;8(8) doi: 10.1371/journal.pone.0071818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0071818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasreen S., Calzavara A.J., Sundaram M.E., et al.  Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study. BMJ Open. 2021;11(12)</Citation>
        </Reference>
        <Reference>
          <Citation>Gubernot D, Jazwa A, Niu M, et al. U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines. Vaccine 2021;39(28):3666–77. doi: 10.1016/j.vaccine.2021.05.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2021.05.016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X., Ostropolets A., Makadia R., et al.  Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021;373 doi: 10.1136/bmj.n1435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n1435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>International statistical classification of diseases and related health problems, tenth revision, Canada (ICD-10-CA). Ottawa, Ontario, Canada: Canadian Institute for Health Information; 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Wormsbecker A.E., Johnson C., Bourns L., et al.  Demonstration of background rates of three conditions of interest for vaccine safety surveillance. PLoS One. 2019;14(1) doi: 10.1371/journal.pone.0210833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0210833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willame C., Dodd C., Gini R., et al.  Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines (2.0) Zenodo. 2021 doi: 10.5281/zenodo.5255870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5281/zenodo.5255870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fay M.P., Feuer E.J. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med. 1997;16(7):791–801. doi: 10.1002/(sici)1097-0258(19970415)16:7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(sici)1097-0258(19970415)16:7</ArticleId>
            <ArticleId IdType="pubmed">9131766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kytö V., Sipilä J., Rautava P. The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood. Heart. 2013;99(22):1681–1684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24064227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vasudeva R., Bhatt P., Lilje C., et al.  Trends in Acute Myocarditis Related Pediatric Hospitalizations in the United States, 2007–2016. Am J Cardiol. 2021;149:95–102. doi: 10.1016/j.amjcard.2021.03.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjcard.2021.03.019</ArticleId>
            <ArticleId IdType="pubmed">33757784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ontario Agency for Health Protection and Promotion (Public Health Ontario). Ontario respiratory pathogen bulletin [Internet]. Toronto, ON: Queen’s Printer for Ontario; 2021 [Available from: https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/respiratory-pathogens-weekly/respiratory-pathogens-historical [accessed November 25 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Government of Ontario. Guide to reopening Ontario’s schools: Queen's Printer for Ontario; 2020 [Available from: https://www.ontario.ca/page/guide-reopening-ontarios-schools [accessed November 25 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>Bhatia R.S., Chu C., Pang A., et al.  Virtual care use before and during the COVID-19 pandemic: a repeated cross-sectional study. CMAJ Open. 2021;9(1):E107. doi: 10.9778/cmajo.20200311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.9778/cmajo.20200311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rasmussen T.A., Jørgensen M.R.S., Bjerrum S., et al.  Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. BMJ. 2012;345 doi: 10.1136/bmj.e5823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.e5823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burns J.C., Herzog L., Fabri O., et al.  Seasonality of Kawasaki disease: a global perspective. PLoS One. 2013;8(9):e74529–e74629. doi: 10.1371/journal.pone.0074529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0074529</ArticleId>
            <ArticleId IdType="pmc">PMC3776809</ArticleId>
            <ArticleId IdType="pubmed">24058585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mikkonen K., Uhari M., Pokka T., et al.  Diurnal and seasonal occurrence of febrile seizures. Pediatr Neurol. 2015;52(4):424–427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25682483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juurlink D, Preyra C, Croxford R, et al. Canadian Institute for Health Information Discharge Abstract Database: A Validation Study Toronto: Institute for Clinical Evaluative Sciences; 2006 [Available from: https://www.ices.on.ca/flip-publication/canadian-istitute-for-health-information-discharge/files/assets/basic-html/index.html#9.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
